Las Vegas, NV -- (SBWIRE) -- 01/08/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: SUPERVALU INC. (NYSE:SVU), GT Advanced Technologies Inc (NASDAQ:GTAT), Novavax, Inc. (NASDAQ:NVAX), Exelixis, Inc. (NASDAQ:EXEL)
SUPERVALU INC. (NYSE:SVU) opened the session at $6.96, trading in a range of $6.88 - $7.15, and closed at $7.04. The stock showed a positive performance of +1.59% in the last trading session. The stock traded on a volume of 5.95 million shares and the average volume of the stock remained 3.51 million shares. SUPERVALU INC., together with its subsidiaries, operates as a wholesale distributor to independent retail customers in the United States. It operates in three segments: Retail Food, Save-A-Lot, and Independent Business.
Will SVU Continue To Move Higher? Find Out Here
GT Advanced Technologies Inc (NASDAQ:GTAT) traded 5.81 million shares in the last business day while the average volume of the stock remained 5.30 million shares. The stock showed a positive movement of +3.10% to end at $9.31. The 52 week range of the stock remained $2.61 - $10.75. GT Advanced Technologies Inc. is diversified technology company with crystal growth equipment and solutions for the global solar, light emitting diode (LED) and electronics industries. The Company operates in three segments: its polysilicon business, its photovoltaic (PV), business and its sapphire business.
For How Long GTAT will fight for Profitability? Read This Trend Analysis report
Novavax, Inc. (NASDAQ:NVAX) reported 5.57 million shares were exchanged during the last trade, while the average volume is about 6.04 million shares. The stock dropped -3.93% and finished the day at $5.01. The beta of the stock is recorded at 2.44. Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company?s technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines.
Why Should Investors Buy NVAX After the Recent Fall? Just Go Here and Find Out
Exelixis, Inc. (NASDAQ:EXEL) the stock advanced +0.51% and finished the session at $6.84. Traded with volume of 5.11 million shares in the prior session and the average volume of the stock remained 1.56 million shares. Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer.
Will EXEL Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)